Evidence map›Paper›PMID 42543488›Full record

ArticleClinical and translational allergy2026

Criteria for Control and Remission of Respiratory Allergic Disease With Allergen Immunotherapy: A Delphi Consensus.

Eloína González-Mancebo, Juan María Beitia Mazuecos, Ana I Tabar Purroy, Mar Gandolfo-Cano, Adriana Izquierdo-Domínguez, María José Castillo Marchuet, Cristina Cuevas Bravo, Leticia Domínguez Cereijo, Alicia Enríquez-Matas, Ignacio Esteban Gorgojo and 2 more

Abstract read
In one paragraph

Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eloína González-ManceboUnidad de Alergología, Hospital Universitario de Fuenlabrada, Madrid, Spain.ORCID https://orcid.org/0000-0003-3982-9273
Juan María Beitia MazuecosUnidad de Alergología, Hospital Universitario de Fuenlabrada, Madrid, Spain.ORCID https://orcid.org/0000-0002-9776-2321
Ana I Tabar PurroyImmunotherapy Committee of the SEAIC, Madrid, Spain.ORCID https://orcid.org/0000-0003-2586-086X
Mar Gandolfo-CanoServicio de Alergología, Hospital Universitario La Paz, Madrid, Spain.ORCID https://orcid.org/0000-0002-9527-4244
Adriana Izquierdo-DomínguezServicio de Alergología, Hospital Universitario Consorci Sanitari de Terrasa, Grupo de investigación InOIA (investigación en olfato, inmunología y alergia), Unidad Alergo-Rino, Teknon, Barcelona, Spain.ORCID https://orcid.org/0000-0002-6124-5197
María José Castillo MarchuetImmunotherapy Committee of the SEAIC, Madrid, Spain.ORCID https://orcid.org/0000-0002-1938-2403
Cristina Cuevas BravoImmunotherapy Committee of the SEAIC, Madrid, Spain.ORCID https://orcid.org/0000-0003-0111-1514
Leticia Domínguez CereijoImmunotherapy Committee of the SEAIC, Madrid, Spain.
Alicia Enríquez-MatasImmunotherapy Committee of the SEAIC, Madrid, Spain.ORCID https://orcid.org/0000-0001-5517-6933
Ignacio Esteban GorgojoImmunotherapy Committee of the SEAIC, Madrid, Spain.
Adrián Germán SánchezImmunotherapy Committee of the SEAIC, Madrid, Spain.
Alba Juárez GuerreroImmunotherapy Committee of the SEAIC, Madrid, Spain.

Funding

Allergy Therapeutics Ibérica, S.L.U.
6 · The paper itself

Abstract

backgroundAllergic rhinitis, conjunctivitis and asthma are prevalent IgE-mediated respiratory diseases that frequently coexist and impair quality of life. Allergen immunotherapy (AIT) has clinical benefits and potential disease-modifying effects. Until recently, standardised definitions of disease control and remission were lacking in routine clinical practice, particularly for allergic rhinitis and conjunctivitis. This study aimed to propose preliminary definitions of control and remission in patients receiving AIT and to assess expert consensus using the Delphi methodology.

methodsA scientific committee developed a survey based on a literature review and expert input, addressing symptoms, medication use, quality of life, exacerbations and tools for objective and subjective assessment. Forty allergists participated in a two-round Delphi study. Consensus was predefined as ≥ 70% agreement on a 9-point Likert scale.

resultsConsensus was achieved for all items after two rounds. The panel agreed on proposed definitions of disease control and clinical remission for allergic rhinitis, conjunctivitis and asthma in the context of AIT, integrating symptom severity, medication use, validated questionnaires and objective measures.

conclusionsThis study presents preliminary expert-consensus definitions of control and remission in allergic rhinitis, conjunctivitis and asthma in patients undergoing AIT. These definitions should not be interpreted as validated clinical criteria or endpoints. As a preliminary proposal, they aim to provide a structured approach for assessing treatment response in clinical practice by integrating symptom burden, medication use, patient-reported outcomes and objective measures. They should be regarded as an initial conceptual step, and further prospective studies are needed to validate these criteria and confirm their relevance, feasibility and applicability.

Indexed as

allergen immunotherapyallergic asthmaallergic rhino‐conjunctivitiscontrol and remission criteriaDelphi method

Identifiers

PMID42543488
PMCPMC13429802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.